A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...
Zacks Investment Research on MSN12h
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits FailureThis week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
GlobalData on MSN17h
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditionsSanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...
The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback